Skip to main content
Top
Published in: AIDS and Behavior 9/2014

01-09-2014 | Original Paper

Drug Users’ Willingness to Encourage Social, Sexual, and Drug Network Members to Receive an HIV Vaccine: A Social Network Analysis

Authors: A. M. Young, R. J. DiClemente, D. S. Halgin, C. E. Sterk, J. R. Havens

Published in: AIDS and Behavior | Issue 9/2014

Login to get access

Abstract

This study examined feasibility of peer-based promotion of HIV vaccination and dyadic correlates to vaccine encouragement in risk- and non-risk networks of drug users (n = 433) in the US. Data were collected on HIV vaccine attitudes, risk compensation intentions, likelihood of encouraging vaccination, and recent (past 6 months) risk (i.e. involving sex and/or injecting drugs) and non-risk (i.e. involving co-usage of noninjected drugs and/or social support) relationships. Willingness to encourage HIV vaccination was reported in 521 and 555 risk- and non-risk relationships, respectively. However, 37 % expressed hesitancy, typically due to fear of side effects or social concerns. Encouragement was often motivated by perceived HIV risk, though 9 % were motivated by risk compensation intentions. In non-risk partnerships, encouragement was associated with drug co-usage, and in risk relationships, with perceived vaccine acceptability and encouragement by the partner. Network-based HIV vaccine promotion may be a successful strategy, but risk compensation intentions should be explored.
Literature
1.
go back to reference Fonseca MGP, Forsythe S, Menezes A, et al. Modeling HIV vaccines in Brazil: assessing the impact of a future HIV vaccine on reducing new infections, mortality and number of people receiving ARV. PLoS One. 2010;5(7):e11736.PubMedCentralPubMedCrossRef Fonseca MGP, Forsythe S, Menezes A, et al. Modeling HIV vaccines in Brazil: assessing the impact of a future HIV vaccine on reducing new infections, mortality and number of people receiving ARV. PLoS One. 2010;5(7):e11736.PubMedCentralPubMedCrossRef
2.
go back to reference Stover J, Bollinger L, Hecht R, Williams C, Roca E. The impact of an AIDS vaccine in developing countries: a new model and initial results. Health Aff. 2007;26(4):1147–58.CrossRef Stover J, Bollinger L, Hecht R, Williams C, Roca E. The impact of an AIDS vaccine in developing countries: a new model and initial results. Health Aff. 2007;26(4):1147–58.CrossRef
3.
go back to reference Andersson KM, Owens DK, Vardas E, Gray GE, McIntyre JA, Paltiel AD. Predicting the impact of a partially effective HIV vaccine and subsequent risk behavior change on the heterosexual HIV epidemic in low- and middle-income countries: a South African example. J Acquir Immune Defic Syndr. 2007;46(1):78–90.PubMedCentralPubMed Andersson KM, Owens DK, Vardas E, Gray GE, McIntyre JA, Paltiel AD. Predicting the impact of a partially effective HIV vaccine and subsequent risk behavior change on the heterosexual HIV epidemic in low- and middle-income countries: a South African example. J Acquir Immune Defic Syndr. 2007;46(1):78–90.PubMedCentralPubMed
4.
go back to reference Newman P, Logie C. HIV vaccine acceptability: a systematic review and meta-analysis. AIDS. 2010;24(11):1749–56.PubMedCrossRef Newman P, Logie C. HIV vaccine acceptability: a systematic review and meta-analysis. AIDS. 2010;24(11):1749–56.PubMedCrossRef
5.
go back to reference Barrington C, Moreno L, Kerrigan D. Local understanding of an HIV vaccine and its relationship with HIV-related stigma in the Dominican Republic. AIDS Care. 2007;19(7):871–7.PubMedCrossRef Barrington C, Moreno L, Kerrigan D. Local understanding of an HIV vaccine and its relationship with HIV-related stigma in the Dominican Republic. AIDS Care. 2007;19(7):871–7.PubMedCrossRef
6.
go back to reference Newman P, Duan N, Rudy ET, Roberts KJ, Swendeman D. Posttrial HIV vaccine adoption: concerns, motivators, and intentions among persons at risk for HIV. J Acquir Immune Defic Syndr. 2004;37(3):1393–403.PubMedCrossRef Newman P, Duan N, Rudy ET, Roberts KJ, Swendeman D. Posttrial HIV vaccine adoption: concerns, motivators, and intentions among persons at risk for HIV. J Acquir Immune Defic Syndr. 2004;37(3):1393–403.PubMedCrossRef
8.
go back to reference Newman P, Woodford MR, Logie C. HIV vaccine acceptability and culturally appropriate dissemination among sexually diverse Aboriginal peoples in Canada. Glob Public Health. 2012;7(1):87–100.PubMedCrossRef Newman P, Woodford MR, Logie C. HIV vaccine acceptability and culturally appropriate dissemination among sexually diverse Aboriginal peoples in Canada. Glob Public Health. 2012;7(1):87–100.PubMedCrossRef
9.
go back to reference Newman P, Roungprakhon S, Tepjan S, Yim S, Walisser R. A social vaccine? Social and structural contexts of HIV vaccine acceptability among most-at-risk populations in Thailand. Glob Public Health. 2012;7(9):1009–24.PubMedCrossRef Newman P, Roungprakhon S, Tepjan S, Yim S, Walisser R. A social vaccine? Social and structural contexts of HIV vaccine acceptability among most-at-risk populations in Thailand. Glob Public Health. 2012;7(9):1009–24.PubMedCrossRef
10.
go back to reference Sayles JN, Macphail CL, Newman P, Cunningham WE. Future HIV vaccine acceptability among young adults in South Africa. Health Educ Behav. 2010;37(2):193–210.PubMedCentralPubMedCrossRef Sayles JN, Macphail CL, Newman P, Cunningham WE. Future HIV vaccine acceptability among young adults in South Africa. Health Educ Behav. 2010;37(2):193–210.PubMedCentralPubMedCrossRef
11.
go back to reference Rudy ET, Newman P, Duan N, Kelly EM, Roberts KJ, Seiden DS. HIV vaccine acceptability among women at risk: perceived barriers and facilitators to future HIV vaccine uptake. AIDS Educ Prev. 2005;17(3):253–67.PubMedCrossRef Rudy ET, Newman P, Duan N, Kelly EM, Roberts KJ, Seiden DS. HIV vaccine acceptability among women at risk: perceived barriers and facilitators to future HIV vaccine uptake. AIDS Educ Prev. 2005;17(3):253–67.PubMedCrossRef
12.
go back to reference Mills E, Cooper C, Guyatt G, et al. Barriers to participating in an HIV vaccine trial: a systematic review. AIDS. 2004;18(17):2235–42.PubMedCrossRef Mills E, Cooper C, Guyatt G, et al. Barriers to participating in an HIV vaccine trial: a systematic review. AIDS. 2004;18(17):2235–42.PubMedCrossRef
13.
go back to reference Lau C-Y, Swann EM, Singh S, Kafaar Z, Meissner HI, Stansbury JP. Conceptual framework for behavioral and social science in HIV vaccine clinical research. Vaccine. 2011;29(44):7794–800.PubMedCentralPubMedCrossRef Lau C-Y, Swann EM, Singh S, Kafaar Z, Meissner HI, Stansbury JP. Conceptual framework for behavioral and social science in HIV vaccine clinical research. Vaccine. 2011;29(44):7794–800.PubMedCentralPubMedCrossRef
14.
go back to reference Lindegger G, Quayle M, Ndlovu M. Local knowledge and experiences of vaccination: implications for HIV-preventive vaccine trials in South Africa. Health Educ Behav. 2007;34(1):108–23.PubMedCrossRef Lindegger G, Quayle M, Ndlovu M. Local knowledge and experiences of vaccination: implications for HIV-preventive vaccine trials in South Africa. Health Educ Behav. 2007;34(1):108–23.PubMedCrossRef
15.
go back to reference Lesch A, Kafaar Z, Kagee A, Swartz L. Community members’ perceptions of enablers and inhibitors to participation in HIV vaccine trials. S Afr J Psychol. 2006;36(4):734–61.CrossRef Lesch A, Kafaar Z, Kagee A, Swartz L. Community members’ perceptions of enablers and inhibitors to participation in HIV vaccine trials. S Afr J Psychol. 2006;36(4):734–61.CrossRef
16.
go back to reference Frew PM, Archibald M, Martinez N, del Rio C, Mulligan MJ. Promoting HIV vaccine research in African American communities: does the theory of reasoned action explain potential outcomes of involvement? Challenge. 2007;13(2):61–97.PubMedCentralPubMed Frew PM, Archibald M, Martinez N, del Rio C, Mulligan MJ. Promoting HIV vaccine research in African American communities: does the theory of reasoned action explain potential outcomes of involvement? Challenge. 2007;13(2):61–97.PubMedCentralPubMed
17.
go back to reference Newman P, Logie C, James L, et al. “Speaking the dialect”: understanding public discourse in the aftermath of an HIV vaccine trial shutdown. Am J Public Health. 2011;101(9):1749–58.PubMedCentralPubMedCrossRef Newman P, Logie C, James L, et al. “Speaking the dialect”: understanding public discourse in the aftermath of an HIV vaccine trial shutdown. Am J Public Health. 2011;101(9):1749–58.PubMedCentralPubMedCrossRef
18.
go back to reference Kelley RT, Hannans A, Kreps GL, Johnson K. The Community Liaison Program: a health education pilot program to increase minority awareness of HIV and acceptance of HIV vaccine trials. Health Educ Res. 2012;27(4):746–54.PubMedCentralPubMedCrossRef Kelley RT, Hannans A, Kreps GL, Johnson K. The Community Liaison Program: a health education pilot program to increase minority awareness of HIV and acceptance of HIV vaccine trials. Health Educ Res. 2012;27(4):746–54.PubMedCentralPubMedCrossRef
19.
go back to reference Jenkins RA, Thapinta D, Morgan PA, et al. Behavioral and social issues among volunteers in a preventive HIV vaccine trial in Thailand. J Acquir Immune Defic Syndr. 2005;40(5):592–9.PubMedCrossRef Jenkins RA, Thapinta D, Morgan PA, et al. Behavioral and social issues among volunteers in a preventive HIV vaccine trial in Thailand. J Acquir Immune Defic Syndr. 2005;40(5):592–9.PubMedCrossRef
20.
go back to reference Allen MA, Liang TS, La Salvia T, Tjugum B, Gulakowski RJ, Murguía M. Assessing the attitudes, knowledge, and awareness of HIV vaccine research among adults in the United States. J Acquir Immune Defic Syndr. 2005;40(5):617–24.PubMedCrossRef Allen MA, Liang TS, La Salvia T, Tjugum B, Gulakowski RJ, Murguía M. Assessing the attitudes, knowledge, and awareness of HIV vaccine research among adults in the United States. J Acquir Immune Defic Syndr. 2005;40(5):617–24.PubMedCrossRef
21.
go back to reference Frew PM, Archibald M, Hixson B, del Rio C. Socioecological influences on community involvement in HIV vaccine research. Vaccine. 2011;29(36):6136–43.PubMedCentralPubMedCrossRef Frew PM, Archibald M, Hixson B, del Rio C. Socioecological influences on community involvement in HIV vaccine research. Vaccine. 2011;29(36):6136–43.PubMedCentralPubMedCrossRef
22.
go back to reference Valente TW, Zogg JB, Christensen S, Richardson J, Kovacs A, Operskalski E. Using social networks to recruit an HIV vaccine preparedness cohort. J Acquir Immune Defic Syndr. 2009;52(4):514–23.PubMedCentralPubMedCrossRef Valente TW, Zogg JB, Christensen S, Richardson J, Kovacs A, Operskalski E. Using social networks to recruit an HIV vaccine preparedness cohort. J Acquir Immune Defic Syndr. 2009;52(4):514–23.PubMedCentralPubMedCrossRef
23.
go back to reference Havens J, Lofwall MR, Frost SD, Oser CB, Leukefeld CG, Crosby RA. Individual and network factors associated with prevalent hepatitis C infection among rural Appalachian injection drug users. Am J Public Health. 2013;103(1):e44–52.PubMedCentralPubMedCrossRef Havens J, Lofwall MR, Frost SD, Oser CB, Leukefeld CG, Crosby RA. Individual and network factors associated with prevalent hepatitis C infection among rural Appalachian injection drug users. Am J Public Health. 2013;103(1):e44–52.PubMedCentralPubMedCrossRef
24.
go back to reference Young A, Jonas A, Mullins U, Halgin D, Havens J. Network structure and the risk for HIV transmission among rural drug users. AIDS Behav. 2013;17(7):2341–51.PubMedCrossRef Young A, Jonas A, Mullins U, Halgin D, Havens J. Network structure and the risk for HIV transmission among rural drug users. AIDS Behav. 2013;17(7):2341–51.PubMedCrossRef
26.
go back to reference Woodhouse DE, Rothenberg R, Potterat J, et al. Mapping a social network of heterosexuals at high risk for human immunodeficiency virus infection. AIDS. 1994;8:1331–6.PubMedCrossRef Woodhouse DE, Rothenberg R, Potterat J, et al. Mapping a social network of heterosexuals at high risk for human immunodeficiency virus infection. AIDS. 1994;8:1331–6.PubMedCrossRef
27.
go back to reference Rothenberg R, Woodhouse DE, Potterat J, Muth JB, Darrow WW, Klovadahl AS. Social networks in disease transmission: the Colorado Springs Study. NIDA Res Monogr. 1995;151:3–19.PubMed Rothenberg R, Woodhouse DE, Potterat J, Muth JB, Darrow WW, Klovadahl AS. Social networks in disease transmission: the Colorado Springs Study. NIDA Res Monogr. 1995;151:3–19.PubMed
28.
go back to reference Borgatti S. Netdraw network visualization [computer program]. Version 2.095. Harvard, MA: Analytic Technologies; 2002. Borgatti S. Netdraw network visualization [computer program]. Version 2.095. Harvard, MA: Analytic Technologies; 2002.
29.
go back to reference Fishbein M. An integrative model for behavioral prediction and its application to health promotion. In: DiClemente RJ, Crosby RA, Kegler MC, editors. Emerging theories in health promotion practice and research. San Francisco: Wiley; 2009. Fishbein M. An integrative model for behavioral prediction and its application to health promotion. In: DiClemente RJ, Crosby RA, Kegler MC, editors. Emerging theories in health promotion practice and research. San Francisco: Wiley; 2009.
30.
go back to reference Cialdini RB, Reno RR, Kallgren CA. A focus theory of normative conduct: recycling the concept of norms to reduce littering in public places. J Pers Soc Psychol. 1990;58(6):1015–26.CrossRef Cialdini RB, Reno RR, Kallgren CA. A focus theory of normative conduct: recycling the concept of norms to reduce littering in public places. J Pers Soc Psychol. 1990;58(6):1015–26.CrossRef
31.
go back to reference SAS Institute. The GLIMMIX procedure. SAS/STAT 9.3 user’s guide. Cary, NC: SAS Institute; 2011. SAS Institute. The GLIMMIX procedure. SAS/STAT 9.3 user’s guide. Cary, NC: SAS Institute; 2011.
32.
go back to reference Šidák Z. Rectangular confidence regions for the means of multivariate normal distributions. J Am Stat Assoc. 1967;62(318):626–33. Šidák Z. Rectangular confidence regions for the means of multivariate normal distributions. J Am Stat Assoc. 1967;62(318):626–33.
34.
go back to reference Mahajan AP, Sayles JN, Patel VA, et al. Stigma in the HIV/AIDS epidemic: a review of the literature and recommendations for the way forward. AIDS. 2008;22(Suppl 2):S67.PubMedCentralPubMedCrossRef Mahajan AP, Sayles JN, Patel VA, et al. Stigma in the HIV/AIDS epidemic: a review of the literature and recommendations for the way forward. AIDS. 2008;22(Suppl 2):S67.PubMedCentralPubMedCrossRef
35.
go back to reference Newman P, Duan N, Rudy ET, Johnston-Roberts K. HIV risk and prevention in a post-vaccine context. Vaccine. 2004;22(15–16):1954–63.PubMedCrossRef Newman P, Duan N, Rudy ET, Johnston-Roberts K. HIV risk and prevention in a post-vaccine context. Vaccine. 2004;22(15–16):1954–63.PubMedCrossRef
36.
go back to reference Newman P, Lee SJ, Duan N, et al. Preventive HIV vaccine acceptability and behavioral risk compensation among a random sample of high-risk adults in Los Angeles (LA VOICES). Health Serv Res. 2009;44(6):2167–79.PubMedCentralPubMedCrossRef Newman P, Lee SJ, Duan N, et al. Preventive HIV vaccine acceptability and behavioral risk compensation among a random sample of high-risk adults in Los Angeles (LA VOICES). Health Serv Res. 2009;44(6):2167–79.PubMedCentralPubMedCrossRef
37.
go back to reference van Griensvan F, Keawkungwal J, Tappero JW, et al. Lack of increased HIV risk behavior among injection drug users participating in the AIDSVAX B/E HIV vaccine trial in Bangkok, Thailand. AIDS. 2004;18(2):295–301.PubMedCrossRef van Griensvan F, Keawkungwal J, Tappero JW, et al. Lack of increased HIV risk behavior among injection drug users participating in the AIDSVAX B/E HIV vaccine trial in Bangkok, Thailand. AIDS. 2004;18(2):295–301.PubMedCrossRef
38.
go back to reference Newman P, Roungprakhon S, Tepjan S, Yim S. Preventive HIV vaccine acceptability and behavioral risk compensation among high-risk men who have sex with men and transgenders in Thailand. Vaccine. 2010;28:958–64.PubMedCrossRef Newman P, Roungprakhon S, Tepjan S, Yim S. Preventive HIV vaccine acceptability and behavioral risk compensation among high-risk men who have sex with men and transgenders in Thailand. Vaccine. 2010;28:958–64.PubMedCrossRef
39.
go back to reference Andersson KM, Paltiel AD, Owens DK. The potential impact of an HIV vaccine with rapidly waning protection on the epidemic in Southern Africa: examining the RV144 trial results. Vaccine. 2011;29(36):6107–12.PubMedCentralPubMedCrossRef Andersson KM, Paltiel AD, Owens DK. The potential impact of an HIV vaccine with rapidly waning protection on the epidemic in Southern Africa: examining the RV144 trial results. Vaccine. 2011;29(36):6107–12.PubMedCentralPubMedCrossRef
40.
go back to reference Bogard E, Kuntz KM. The impact of a partially effective HIV vaccine on a population of intravenous drug users in Bangkok, Thailand: a dynamic model. J Acquir Immune Defic Syndr. 2002;29(2):132–41.PubMedCrossRef Bogard E, Kuntz KM. The impact of a partially effective HIV vaccine on a population of intravenous drug users in Bangkok, Thailand: a dynamic model. J Acquir Immune Defic Syndr. 2002;29(2):132–41.PubMedCrossRef
41.
go back to reference Gray RH, Li X, Wawer MJ, et al. Stochastic simulation of the impact of antiretroviral therapy and HIV vaccines on HIV transmission; Rakai, Uganda. AIDS. 2003;17(13):1941–51.PubMedCrossRef Gray RH, Li X, Wawer MJ, et al. Stochastic simulation of the impact of antiretroviral therapy and HIV vaccines on HIV transmission; Rakai, Uganda. AIDS. 2003;17(13):1941–51.PubMedCrossRef
42.
go back to reference Poole G. Using psychological principles to narrow the intention-behavior gap and increase participation in HIV vaccine trials. Curr HIV Res. 2012;10(6):552–6.PubMedCrossRef Poole G. Using psychological principles to narrow the intention-behavior gap and increase participation in HIV vaccine trials. Curr HIV Res. 2012;10(6):552–6.PubMedCrossRef
43.
go back to reference Young A, Havens J. Transition from first illicit drug use to first injection drug use among rural Appalachian drug users: a cross-sectional comparison and retrospective survival analysis. Addiction. 2012;107(3):587–96.PubMedCentralPubMedCrossRef Young A, Havens J. Transition from first illicit drug use to first injection drug use among rural Appalachian drug users: a cross-sectional comparison and retrospective survival analysis. Addiction. 2012;107(3):587–96.PubMedCentralPubMedCrossRef
44.
go back to reference Crosby R, Oser CB, Leukefeld CG, Havens J, Young A. Prevalence of HIV and risky sexual behaviors among rural drug users: does age matter? Ann Epidemiol. 2012;22(11):778–82.PubMedCentralPubMedCrossRef Crosby R, Oser CB, Leukefeld CG, Havens J, Young A. Prevalence of HIV and risky sexual behaviors among rural drug users: does age matter? Ann Epidemiol. 2012;22(11):778–82.PubMedCentralPubMedCrossRef
45.
go back to reference Kentucky Cabinet for Health and Human Services. An integrated epidemiologic profile for HIV/AIDS prevention and care planning for Kentucky—2010. Frankfort, KY: Department for Public Health, HIV/AIDS Branch; 2012. Kentucky Cabinet for Health and Human Services. An integrated epidemiologic profile for HIV/AIDS prevention and care planning for Kentucky—2010. Frankfort, KY: Department for Public Health, HIV/AIDS Branch; 2012.
Metadata
Title
Drug Users’ Willingness to Encourage Social, Sexual, and Drug Network Members to Receive an HIV Vaccine: A Social Network Analysis
Authors
A. M. Young
R. J. DiClemente
D. S. Halgin
C. E. Sterk
J. R. Havens
Publication date
01-09-2014
Publisher
Springer US
Published in
AIDS and Behavior / Issue 9/2014
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-014-0797-9

Other articles of this Issue 9/2014

AIDS and Behavior 9/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.